Author:
Sasaki T,Onishi T,Hoshina A
Publisher
Springer Science and Business Media LLC
Subject
Cancer Research,Urology,Oncology
Reference23 articles.
1. Eisenberger MA, Carducci M . Treatment of hormone-refractory prostate cancer. In: Wein AJ, Kavoussi LR, Novick AC, Partin AW, Peters CA (eds) Cambell-Walsh Urology, Vol 3, 9th edn Sounders: Philadelphia, PA, 2007, 3101–3117.
2. De Voogt HJ, Suciu S, Sylvester R, Pavone-Macaluso M, Smith PH, De Pauw M, Members of the European Organization for Research on Treatment of Cancer Genitourinary Tract Cancer Cooperative Group. Multivariate analysis of prognostic factors in patients with advanced prostatic cancer: results from 2 European Organization for Research on Treatment of Cancer trials. J Urol 1989; 141: 883.
3. Isikawa S, Soloway MS, Van der Zwaag R, Todd B . Prognostic factors in survival free of progression after androgen deprivation therapy for treatment of prostate cancer. J Urol 1989; 141: 1139–1142.
4. Cooperberg MR, Hinotsu S, Namiki M, Ito K, Broering J, Carroll PR et al. Risk assessment among prostate cancer patients receiving primary androgen deprivation therapy. J Clin Oncol 2009; 27: 4306–43136.
5. Matzkin H, Soloway MS, Schellhammer PF, Chodac G, Smith JA, Caplan R et al. Prognostic factors in stage D2 prostate cancer treated with a pure non-steroidal antiandrogen. Cancer 1995; 72: 1055.